Helping colorectal cancer survivors keep up with post-surgery surveillance
Official title: A Pilot Trial to Evaluate the Effectiveness of Navigation, Interactive Web Education, or the Combination of Both to Promote Guideline-Concordant Colorectal Cancer Surveillance Care
Run by Fred Hutchinson Cancer Center · NCT06995924 · Data updated 2026-11-12
This project tests whether patient navigation services, an interactive web program called Current Together After Cancer (CTAC), or both help people with stage I–III colorectal cancer keep up with recommended post-surgery surveillance.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | Fred Hutchinson Cancer Center Academic / other |
| Locations | 2 sites (Seattle, Washington and 1 other locations) |
| Status | Recruiting |
| Started | November 17, 2025 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2027 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT06995924 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) with stage I–III colorectal cancer who are within three months of standard surgical resection and receive care at a participating clinic and can complete surveys in English.
✕Probably not a fit
Patients who are treated outside the participating Seattle clinics, are more than three months post-surgery, are under 18, or cannot complete English surveys are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot assigns patients to one of three arms based on the clinic where they receive care: navigation only, CTAC web education only, or both navigation and CTAC. Navigation includes education about surveillance, reminders, and scheduling assistance, while CTAC provides self-directed interactive web education and a checklist of recommended tests. Participants are enrolled within three months of surgical resection and followed at about 3 months after enrollment and again 12–18 months after surgery to measure receipt of recommended laboratory tests, imaging, and endoscopy. The trial tests whether these supports increase adherence to guideline-recommended surveillance in stage I–III colorectal cancer survivors.
Why it matters
Potential benefit: If successful, this approach could increase the number of colorectal cancer survivors who get timely surveillance tests and enable earlier detection of recurrence.
How similar studies have gone: Previous work in cancer care and chronic disease has shown that navigation and web-based education can improve follow-up and screening adherence, though results have been mixed and the combined approach for colorectal cancer surveillance is not yet well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 due to disease and clinic population * Stage I-III CRC survivor within 3 months post-surgical resection * Being seen at a participating clinic * Ability to understand and complete surveys in English
Where it's running
-
Benaroya Research Institute at Virginia Mason
Seattle, Washington, United States Recruiting -
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Rachel B. Issaka, MD, MAS — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Ari Bell-Brown
- Email: abellbro@fredhutch.org
- Phone: 206.667.7624
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Zanidatamab given before surgery for HER2-positive colon or rectal cancer
This tests whether giving zanidatamab before surgery helps adults with HER2-positive, RAS‑wildtype colon or rectal cancer who are planned for curative treatment.
-
Family genetics: who shares test results with relatives
This study tests whether letting patients share genetic results with their relatives is as good as doctors sharing the results to help first-degree relatives get genetic testing for hereditary cancer risk.
-
Assessing minimal residual disease in colorectal cancer patients
This study is testing if checking for certain cancer-related markers in the blood can help predict if colorectal cancer will come back after treatment.
-
Combining botensilimab and balstilimab after standard treatment for colorectal cancer
This phase 2 trial tests whether giving botensilimab and balstilimab after standard therapy can clear detectable ctDNA in adults with stage II/III colorectal cancer.
-
Comparing two blood tests to find colorectal cancer coming back after surgery
This tests whether the Haystack blood test finds returning colorectal cancer earlier than the Signatera test in adults who have had curative surgery for stage II–IV disease.
-
Pidnarulex plus cemiplimab for refractory microsatellite-stable colorectal cancer.
This tests whether combining pidnarulex with cemiplimab is safe and can help people whose microsatellite-stable colorectal cancer has stopped responding to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.